Monica Niger
Council
About
Monica Niger works as medical oncologist at National Cancer Institute Fondazione IRCCS of Milan and is responsible for the management and clinical/translational research of biliary tract cancer and pancreatic cancer at her Institution.
She obtained her medical degree from the University of Milan in 2011 and the specialization in Medical Oncology in 2017 at the University of Milan.
Dr. Niger’s clinical and research interests primarily focus on gastrointestinal malignancies, with a specific emphasis on biliopancreatic cancer. She is actively involved in the clinical management of patients suffering from these aggressive diseases and is dedicated to designing and collaborating in clinical and translational collaborative research projects in this field.
She has co-authored more than 80 publications in international journals and she is full member of Associazione Italiana di Oncologia Medica (AIOM), European Society for Medical Oncology (ESMO) and European Organisation for Research and Treatment of Cancer (EORTC).
Publications
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO
Ann Oncol. 2024 Dec
doi: 10.1016/j.annonc.2024.11.016 – PMID: 39637944.
The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Phase 1b/2a Trial
Clin Cancer Res. 2024 Dec 2
doi: 10.1158/1078-0432.CCR-24-2611 – PMID: 39620921.
Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer
Cancer Med. 2024 Dec;13(23):e70393.
doi: 10.1002/cam4.70393. – PMID: 39618336.
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial
Lancet Oncol. 2024 Dec;25(12):1539-1550.
doi: 10.1016/S1470-2045(24)00580-1. – PMID: 39557058.
Liver Transplantation for Intrahepatic Cholangiocarcinoma After Chemotherapy and Radioembolization: An Intention-To-Treat Study
Transpl Int. 2024 Oct 31:37:13641.
doi: 10.3389/ti.2024.13641. – PMID: 39544321.
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population
Oncologist. 2024 Oct 19:oyae256.
doi: 10.1093/oncolo/oyae256. – PMID: 39427227.
Is tumour sequencing effective for the identification of germline BRCA1/2 pathogenic variant carriers?
Oncologist. 2024 Oct 19:oyae256.
DOI: 10.1177/03008916241280127. – PMID: 39311051.
Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial.
Eur J Cancer. 2024 Sep;209:114276.
DOI: 10.1016/j.ejca.2024.114276. – PMID: 39128186.
NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
JAMA Netw Open. 2024 Jan 2;7(1):e2350756.
doi: 10.1001/jamanetworkopen.2023.50756. – PMID: 38190183
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2
J Hematol Oncol. 2023 Dec 14;16(1):119.
doi: 10.1186/s13045-023-01510-9. – PMID: 38098114